BioSkryb: Advanced Single-Cell DNA Analysis Solutions
BioSkryb Genomics is revolutionizing the field of single-cell DNA analysis with cutting-edge genomic tools. Their innovative approach to precision medicine is setting new standards in the industry. The company’s patented Primary Template-directed Amplification (PTA) technology achieves remarkable genome recovery rates exceeding 95%, coupled with unparalleled coverage uniformity1.
BioSkryb’s suite of solutions includes ResolveOME, which enables simultaneous genome and transcriptome amplification, and ResolveDNA for single-cell genomics. These advanced tools are complemented by the BaseJumper bioinformatics platform, offering a comprehensive ecosystem for researchers12.
Based in Durham, North Carolina, BioSkryb is at the forefront of developing more precise treatments through single-cell analysis. Their technology is paving the way for breakthroughs in various fields, including oncology, neurology, and immunology2.
Key Takeaways
- BioSkryb offers high-precision single-cell DNA analysis tools
- PTA technology provides over 95% genome recovery
- ResolveOME enables simultaneous genome and transcriptome analysis
- BaseJumper platform supports comprehensive bioinformatics
- BioSkryb’s solutions are advancing precision medicine
- Applications span oncology, neurology, and immunology
Introduction to BioSkryb
BioSkryb Genomics stands at the forefront of genetic research, revolutionizing single-cell analysis. This innovative company empowers scientists to explore the intricate world of cellular heterogeneity with unprecedented precision.
What is BioSkryb?
BioSkryb Genomics specializes in developing cutting-edge tools for single-cell whole genome and transcriptome amplification. Their flagship product, ResolveDNA, offers unparalleled genomic coverage from a single cell, with significantly lower allelic dropout compared to existing methods3. The ResolveDNA workflow is designed for efficiency, requiring less than 30 minutes of hands-on time and compatible with both automated and manual setups3.
Importance of Single-Cell DNA Analysis
Single-cell analysis is crucial for understanding cellular heterogeneity, which drives human diversity and disease development. BioSkryb’s technology enables scientists to gain an unprecedented view of the genome, transcriptome, and proteome within individual cells. This level of detail is essential for exploring the relationship between genes and disease, advancing precision medicine.
| Feature | BioSkryb’s ResolveDNA | Traditional Methods |
|---|---|---|
| Genome Recovery | Over 95% | Lower recovery rates |
| Allelic Dropout | Significantly lower | Higher dropout rates |
| Workflow Time | Less than 30 minutes | Typically longer |
| Scalability | Up to 384 reactions per kit | Often limited |
BioSkryb’s ResolveOME product solution addresses the challenges of data quality in high coverage genome analysis, overcoming limitations of previous methodologies like Multiple Displacement Amplification (MDA)4. The unique chemistry system minimizes recopying of synthesized genome amplicons and cDNA, resulting in a pool of amplified genome containing the complete diversity of cDNA in a cell4.
“BioSkryb Genomics is transforming our understanding of cellular diversity, one cell at a time.”
Innovative Technology Behind BioSkryb
BioSkryb’s cutting-edge technology is transforming genetic analysis. The company’s groundbreaking approach offers unparalleled insights into cellular genetics, pushing the boundaries of what’s possible in genomic research.
Key Features of the Technology
At the heart of BioSkryb’s innovation lies Primary Template-directed Amplification (PTA). This patented technology forms the backbone of their ResolveDNA platform, which achieves remarkable genome recovery rates exceeding 95%5. The ResolveOME system takes this a step further, enabling simultaneous amplification of both genome and transcriptome from a single cell.
Comparison with Traditional Methods
Unlike conventional amplification techniques, BioSkryb’s technology significantly reduces biases and experimental artifacts. This results in superior genomic coverage and unprecedented resolution. The ResolveDNA core kit allows for comprehensive analyses of genetic variations, including single nucleotide variants, copy number variations, and structural variants from individual cell genomes6.
| Feature | Traditional Methods | BioSkryb Technology |
|---|---|---|
| Genome Recovery | Variable | >95% |
| Bias Reduction | Limited | Significant |
| Multiomic Analysis | Separate workflows | Unified workflow |
Future of Genetic Analysis
BioSkryb is shaping the future of genetic analysis through partnerships with leading initiatives like the Human Cell Atlas, a global consortium with over 3,500 members from 101 countries6. Their technology produces sequencing-ready libraries from single cells in under 8 hours, accelerating research timelines6. As single-cell analysis continues to evolve, BioSkryb’s innovative solutions are poised to drive breakthroughs in fields ranging from cancer research to reproductive health.
Applications of BioSkryb Solutions
BioSkryb’s innovative solutions are revolutionizing multiple fields of scientific research. The company’s Primary Template-directed Amplification (PTA) technology enables scientists to delve deeper into the cellular ecosystem, potentially transforming how we approach diseases like cancer7.
In Cancer Research
BioSkryb’s ResolveDNA, a whole genome amplification kit, is making waves in cancer research7. This tool allows scientists to study cell-to-cell genomic variability, crucial for developing precise and effective treatments. By understanding the unique genetic makeup of individual cancer cells, researchers can target therapies more accurately.
In Genetic Disorders
The ResolveOME kit, which amplifies both whole genome and transcriptome, is a game-changer for studying genetic disorders7. This technology enables researchers to gain a comprehensive view of rare conditions at the single-cell level. By analyzing both DNA and RNA simultaneously, scientists can uncover new insights into the mechanisms behind these disorders.
In Developmental Biology
BioSkryb’s single-cell genomics tools are providing unprecedented insights into developmental biology. Researchers can now track genetic changes throughout cellular development, offering a new understanding of human health at the most fundamental level. This could lead to breakthroughs in regenerative medicine and stem cell research.
With its expanding presence in Europe and growing team of experts, BioSkryb is poised to drive significant advancements across these fields77. The company’s commitment to innovation and research is evident in its rapid growth and substantial funding, signaling a bright future for single-cell analysis in biomedical research.
How BioSkryb Works
BioSkryb’s innovative approach to single-cell DNA analysis revolutionizes genomic research. The company’s workflow combines cutting-edge technologies for sample preparation, sequencing, and data analysis.
Sample Preparation
BioSkryb’s sample preparation process uses proprietary technologies to isolate and prepare individual cells for analysis. The ResolveDNA chemistry shows high uniformity in single-cell genomic amplification, with tests analyzing thousands of cells revealing high DNA yield across samples8.
Sequencing Process
The sequencing stage uses ResolveDNA or ResolveOME for genome and transcriptome amplification. This technology enables true single-cell genomic and multiomic analysis across fields like oncology, neurology, and reproductive genomics8. ResolveDNA reproduces genomes of single cells to analyze genomic heterogeneity, while ResolveOME combines whole genome/exome analysis with whole transcriptome analysis within each cell9.
Data Analysis Techniques
BioSkryb’s BaseJumper bioinformatics platform powers the data analysis phase. This platform allows quick analysis of complex data at scale, visualizing results in an intuitive layout. The single-cell whole genome amplification technique enables projects analyzing tens of thousands of cells, reducing costs for large sample projects8.
| Component | Function | Key Benefit |
|---|---|---|
| ResolveDNA | Single-cell genome amplification | High uniformity and yield |
| ResolveOME | Genome/transcriptome analysis | Comprehensive single-cell view |
| BaseJumper | Data analysis and visualization | Quick, scalable analysis |
BioSkryb’s technology opens new exploration possibilities in various fields, generating single-cell genomic and multiomic data on an unprecedented scale8. This comprehensive approach provides researchers with powerful tools to drive discoveries in complex molecular characteristics of single-cell genomics.
Advantages of Using BioSkryb
BioSkryb offers cutting-edge solutions for single-cell DNA analysis, setting new standards in the field. Let’s explore the key advantages that make BioSkryb stand out.
High Sensitivity and Accuracy
BioSkryb’s Primary Template-directed Amplification (PTA) method achieves remarkable genome recovery rates. It reproducibly captures over 95% of single-cell genomes with superior coverage uniformity10. This high level of sensitivity enables accurate variant analysis, including SNPs, indels, SNVs, and CNVs10. The PTA technology limits priming and amplification biases, errors, and allelic skewing, resulting in significantly improved variant call rates compared to traditional methods like Multiple Displacement Amplification (MDA)10.
User-Friendly Interfaces
BioSkryb’s BaseJumper platform provides intuitive interfaces for data visualization and analysis. This user-friendly approach simplifies complex genomic data interpretation, making it accessible to researchers across various fields. The platform’s design facilitates single-cell genome sequencing analysis, enhancing the overall user experience.
Fast Turnaround Time
BioSkryb’s technologies enable rapid single-cell genomic and transcriptomic analyses. The PTA method can be performed directly from single cells collected through various methods, from multiple cells, or with ultra-low inputs of DNA ranging from >4 pg to 10 ng10. This flexibility, combined with efficient workflows, accelerates research and discovery processes. The ResolveDNA® scDNAseq kits and services have demonstrated impressive capabilities, detecting over 85% of off-target indels missed by predictive algorithms11.
| Feature | BioSkryb Advantage |
|---|---|
| Genome Recovery | >95% single-cell genome capture |
| Coverage Uniformity | Superior compared to other methods |
| SNV Calling Sensitivity | Improved variant call rates |
| Turnaround Time | Fast analysis from various sample types |
By combining these advantages, BioSkryb empowers researchers to push the boundaries of single-cell genomics, offering unparalleled insights into cellular diversity and genetic variations.
Case Studies: Success Stories with BioSkryb
BioSkryb’s innovative technologies have paved the way for groundbreaking discoveries in single-cell molecular discovery and precision medicine. Let’s explore some remarkable case studies that showcase the power of BioSkryb’s solutions.
Cancer Research Breakthroughs
In a recent study on postmortem heart tissue, researchers used BioSkryb’s technology to analyze samples from 106 individuals, including 33 with a history of myocardial disease, diabetes, or smoking. Single-cell molecular discovery techniques revealed valuable insights into cellular changes associated with these conditions12.
The study utilized advanced methods to isolate single cardiomyocyte nuclei for DNA and RNA analysis. This approach allowed scientists to uncover that approximately 20.6% of brain cells have at least one Mb-scale copy number variation (CNV), shedding light on potential genetic factors in cancer development1213.
Insights in Rare Genetic Conditions
BioSkryb’s precision medicine tools have proven invaluable in studying rare genetic disorders. In two cases of multiple system atrophy (MSA), researchers found that nearly 30% of cells in affected brain regions had CNVs, providing crucial information about disease progression13.
The company’s whole genome amplification (WGA) methods have shown impressive results. With an MDA reaction volume of 1.25 µL, scientists achieved an estimated assembly coverage increase of up to 90%, enabling more comprehensive genetic analysis of rare conditions14.
| WGA Method | Mean Coverage | Genome Coverage |
|---|---|---|
| PicoPLEX | ~0.64x | 1.71 ± 0.48 Gb |
| PTA | ~0.17x | 2.84 ± 0.56 Gb |
| dMDA | ~0.71x | 0.75 ± 0.29 Gb |
These case studies demonstrate how BioSkryb’s technologies are driving advancements in cancer research and rare genetic disorder studies, pushing the boundaries of precision medicine and offering new hope for patients worldwide.
Collaborations and Partnerships
BioSkryb Genomics stands at the forefront of single-cell analysis, forging strong genomics research collaborations with academic and industry partners. These BioSkryb partnerships drive innovation and expand the reach of cutting-edge technologies in the field.
Key Academic Collaborations
BioSkryb has partnered with the Human Cell Atlas, allowing researchers to use BioSkryb’s single-cell multiomics technology. This collaboration aims to deepen our understanding of biology and disease through high-resolution single-cell analysis.
The company’s Evercode technology enables profiling from 1000 to 1 million cells in a single experiment, capturing lowly expressed genes for higher quality data15. This breakthrough has led to partnerships with over 2,000 labs, advancing research through tailored solutions15.
Industry Partnerships
BioSkryb’s industry partnerships are crucial for global expansion and technology adoption. The appointment of Dr. Ram Laxman as Chief Commercial Officer highlights this focus16. Dr. Laxman’s experience in scaling 10x Genomics’ Asia-Pacific revenue to over $100 million positions BioSkryb for significant growth16.
A recent distribution agreement expands BioSkryb’s services across Singapore and Southeast Asia, showcasing the company’s global strategy16. These partnerships leverage BioSkryb’s ResolveDNA™ technology, which ensures even coverage of the entire genome during DNA amplification17.
Through these collaborations, BioSkryb aims to revolutionize fields like cancer genomics, bacterial genomics, and Minimal Residual Disease testing17. The company’s commitment to innovation and partnership continues to shape the future of single-cell analysis.
Getting Started with BioSkryb
BioSkryb offers cutting-edge solutions for single-cell DNA analysis. Their product lineup includes advanced tools for researchers looking to delve deep into genomic and transcriptomic studies.
Available Products and Services
BioSkryb’s flagship products, ResolveDNA and ResolveOME, stand out for their exceptional performance. The ResolveOME Whole Genome and Transcriptome Amplification Kit provides near-complete coverage of both the genome and mRNA transcriptome, yielding data from a significantly higher proportion of input cells compared to droplet-based methods18.
The ResolveDNA kit achieves over 97% recovery of genomes from single cells with low input DNA samples, showing lower allelic dropout and biases compared to other WGA methods19. This efficiency can lead to reduced sequencing costs for researchers.
Complementing these kits, BioSkryb offers the BaseJumper Bioinformatics Platform. This platform streamlines data processing and variant visualization, making DNA sequencing analysis more efficient19.
Choosing the Right Solution
Selecting the optimal BioSkryb product depends on your research needs:
- For whole genome amplification, the ResolveDNA kit is ideal. It supports various sample types, from single cells to low-input DNA samples ranging from >4 pg to 10 ng19.
- If you need simultaneous genome and transcriptome analysis, the ResolveOME kit is the go-to choice. It allows for the construction of a whole-genome and full-length mRNA transcriptome library from a single cell, completing the process in just one day18.
- For data analysis, the BaseJumper platform offers automated processing and visualization tools, enhancing your research workflow.
By choosing BioSkryb’s solutions, researchers can achieve superior genomic coverage, improved allelic balance, and comprehensive RNA analysis, advancing their studies in fields such as cancer research and genetic disorders1819.
Customer Support and Resources
BioSkryb Genomics stands out in the field of single-cell analysis with its robust customer support and comprehensive resources. The company’s commitment to user success is evident in its array of services and tools designed to empower researchers.
Knowledge Base and Documentation
BioSkryb’s knowledge base is a treasure trove of information for users. It includes detailed product guides for ResolveDNA V2 and V1, which enable whole genome amplification from single cells for next-generation sequencing applications20. The documentation covers ResolveOME, a unified method for amplifying both the whole genome and full-length transcriptome from single cells20. These resources help researchers maximize the potential of BioSkryb’s technologies in their work.
Training and Onboarding Programs
BioSkryb customer support shines through its comprehensive training and onboarding programs. The company offers genomics training tailored to various starting points, from fresh tissues to single cells21. These programs cover crucial aspects like cell sorting, whole genome amplification, and library preparation using specially formulated reagents21.
For those using ResolveOME, BioSkryb provides step-by-step protocols spread across three days, covering amplification, nucleic acid separation, and NGS library prep20. This hands-on approach ensures users can effectively utilize BioSkryb’s products in their research.
BioSkryb’s BaseJumper Bioinformatics Platform offers additional support. This cloud-based solution accelerates genomic exploration, supporting single-cell multiomics data analysis for both DNA and RNA2120. Users can access pre-designed workflows and build datasets from multiomic analyses, enhancing their research capabilities.
With its expert team satisfying customers across academia, biotechnology, and pharmaceutical sectors, BioSkryb’s customer support and resources are designed to propel research forward21.
Future Trends in Single-Cell Analysis
The landscape of genetic analysis is evolving rapidly, with single-cell technologies at the forefront of this revolution. BioSkryb’s innovative solutions are shaping the future of genetic analysis and precision medicine advancements. Their ResolveDNA and ResolveOME single-cell core kits achieve an impressive 97% genomic coverage and 93% allelic balance, setting new standards in the field22.
Innovations on the Horizon
BioSkryb is pushing the boundaries of single-cell analysis with groundbreaking developments. Their latest kits can generate sequencing-ready, DNA-informed multiomic libraries from single cells in under 8 hours, a significant leap in efficiency23. This speed boost allows researchers to dive deeper into genetic mysteries, paving the way for future breakthroughs in precision medicine.
The Role of BioSkryb in Advancing Science
BioSkryb’s contributions to scientific progress are substantial. Their ResolveDNA kit provides unprecedented insights into clonal heterogeneity by resolving complex genomic architectures22. The ResolveOME kit takes this a step further, coupling each cell’s whole genome with its full-length transcriptome22. These advancements are crucial for understanding disease pathogenesis and driving precision medicine forward.
As the future of genetic analysis unfolds, BioSkryb continues to innovate. Their BaseJumper bioinformatics platform offers comprehensive multiomic analysis and data visualization, enabling researchers to generate publication-ready figures22. With these tools, scientists are better equipped to unlock the secrets of cellular processes, bringing us closer to a new era of personalized medicine and targeted therapies.
Q&A
What is BioSkryb Genomics?
BioSkryb Genomics is a company that specializes in single-cell molecular discovery and analysis. They develop innovative technologies for single-cell whole genome and whole transcriptome amplification, enabling unprecedented insights into cellular heterogeneity and genomic variation.
What is Primary Template-directed Amplification (PTA)?
Primary Template-directed Amplification (PTA) is BioSkryb’s patented technology that enables high-fidelity amplification of single-cell genomes. It provides unprecedented genome recovery (>95%) and coverage uniformity, significantly improving upon traditional amplification methods.
What products does BioSkryb offer?
BioSkryb offers several key products: ResolveDNA for single-cell whole genome amplification, ResolveOME for simultaneous genome and transcriptome amplification from the same cell, and the BaseJumper bioinformatics platform for data analysis and visualization.
How does BioSkryb’s technology differ from traditional methods?
BioSkryb’s technology reduces biases, experimental artifacts, and poor reproducibility commonly associated with traditional amplification methods. It provides superior genome recovery and coverage uniformity, allowing for more accurate and comprehensive single-cell analysis.
What are the applications of BioSkryb’s solutions?
BioSkryb’s solutions have wide-ranging applications in various fields, including cancer research, genetic disorder studies, and developmental biology. They help researchers understand cell-to-cell genomic variability, explore rare conditions, and gain insights into physiological processes at the cellular level.
How does the BaseJumper platform work?
The BaseJumper bioinformatics platform provides quick analysis of complex single-cell genomic data at scale. It offers user-friendly interfaces for easy data visualization and analysis, allowing researchers to drive the discovery of complex molecular characteristics in single-cell genomics.
What is the genome recovery rate of BioSkryb’s technology?
BioSkryb’s technology enables an unprecedented genome recovery rate of over 95%, providing researchers with a more comprehensive view of the single-cell genome.
Does BioSkryb offer customer support and training?
Yes, BioSkryb provides comprehensive customer support, including a knowledge base and documentation. They also offer training and onboarding programs to ensure researchers can effectively utilize their products and services.
How is BioSkryb contributing to precision medicine?
By enabling more precise and comprehensive understanding of cellular processes at the single-cell level, BioSkryb is paving the way for breakthroughs in precision medicine. Their technologies help researchers gain insights that can lead to more targeted and effective treatments.
Where is BioSkryb Genomics located?
BioSkryb Genomics is headquartered in Durham, North Carolina.
